▲ Peaking
Business
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.
KRAS-driven
1 news trends Newsylist has tracked involving KRAS-driven — newest first.